Belviq Withdrawn from the US Market Due to Potential Cancer Risk

On February 13, 2020 The U.S. Food and Drug Administration (FDA) requested that the manufacturer of Belviq, Belviq XR (lorcaserin) voluntarily withdraw the weight-loss drug from the U.S. market because a safety clinical trial shows an increased occurrence of cancer with long term use. The drug manufacturer, Eisai has submitted a request to voluntarily withdraw the drug.

Although the risk was small (0.6% increased risk compared to those taking placebo), the FDA felt this warranted removal from the market. There does not appear to be an increased risk of cancer in the initial months of treatment, but the risk is increased with longer duration on Belviq.

You should stop taking Belviq and call the office to schedule an appointment to discuss alternative weight-loss medicines and/or weight management programs.

The FDA is not recommending special screening for patients who have taken Belviq.  As with any individual patient, regardless of prior Belviq treatment, standard screening recommendations for cancer should be implemented.

Author
Scott Isaacs, MD Endocrinologist and Weight Loss Specialist

You Might Also Enjoy...

February is National Heart Health Month

Heart disease doesn’t happen just to older adults. It is happening to younger adults more and more often. This is partly because the conditions that lead to heart disease are happening at younger ages.

2023 Update: Medications for Weight Loss

When people lose weight, their body begins sending signals to the brain that there is a decrease in stored energy. The brain then sends hormonal and chemical messages that increase appetite, hunger, and cravings and decrease metabolism.

January is Healthy Resolutions Month

Some people's challenges are more daunting than others, and it can be disappointing when we abandon our resolutions after only a few weeks. No matter what you have resolved to do this year, it is always best to approach it with a plan.